search button

Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan

  • Authors:
    • Akira Miyazaki
    • Hideaki Miyake
    • Ken‑Ichi Harada
    • Taka‑Aki Inoue
    • Masato Fujisawa

  • View Affiliations

  • Published online on: January 19, 2015     https://doi.org/10.3892/mco.2015.487
  • Pages: 601-606
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this study was to evaluate the oncological efficacy of tyrosine kinase inhibitors (TKIs) as first‑line molecular‑targeted therapy for Japanese patients with metastatic renal cell carcinoma (mRCC) in a routine clinical setting. This study included a total of 271 consecutive Japanese patients with TKI‑naive mRCC, including 172 patients who received sorafenib and 99 who received sunitinib for ≥2 months as a first‑line molecular‑targeted agent. the prognostic outcomes of these patients were retrospectively assessed. During the observation period (median, 19 months), 126 patients (46.5%) succumbed to the disease and the median overall survival (OS) for the entire cohort was 33.1 months. The univariate analysis identified the Memorial Sloan‑Kettering Cancer Center (MSKCC) classification, C‑reactive protein (CRP) level, lymph node metastasis, bone metastasis, liver metastasis, histological subtype and sarcomatoid characteristics as significant predictors of OS. Of these factors, only the MSKCC classification, CRP level and liver metastasis were found to be independently associated with OS in the multivariate analysis. Furthermore, there were significant differences in OS according to the positivity for these 3 independent risk factors (i.e., negative for all factors vs. positive for a single factor vs. positive for 2 or 3 factors). These findings suggest that the introduction of TKIs as first‑line molecular‑targeted agents resulted in favorable cancer control outcomes in Japanese mRCC patients and that the prognosis of these patients may be stratified by 3 potential parameters, including the MSKCC classification, CRP level and liver metastasis.
View Figures
View References

Related Articles

Journal Cover

May-2015
Volume 3 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Miyazaki A, Miyake H, Harada KI, Inoue TA and Fujisawa M: Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan. Mol Clin Oncol 3: 601-606, 2015
APA
Miyazaki, A., Miyake, H., Harada, K., Inoue, T., & Fujisawa, M. (2015). Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan. Molecular and Clinical Oncology, 3, 601-606. https://doi.org/10.3892/mco.2015.487
MLA
Miyazaki, A., Miyake, H., Harada, K., Inoue, T., Fujisawa, M."Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan". Molecular and Clinical Oncology 3.3 (2015): 601-606.
Chicago
Miyazaki, A., Miyake, H., Harada, K., Inoue, T., Fujisawa, M."Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan". Molecular and Clinical Oncology 3, no. 3 (2015): 601-606. https://doi.org/10.3892/mco.2015.487